CommercialDocumentationMedium impact
08.01.33l, Leuprolide (Camcevi™, Eligard®, Fensolvi®, Lupron Depot®)
Independence Blue Cross·Oncology, Urology, Endocrinology·Pharmacy
Effective date
Dec 29, 2025
We identified it
Jun 19, 2026
Summary
This policy update modifies medical necessity criteria and provides general guideline updates for Leuprolide (brand names: Camcevi™, Eligard®, Fensolvi®, Lupron Depot®). The billing team must review updated approval requirements and documentation standards effective immediately to ensure claims are processed correctly and avoid denials.
Action Required
By January 15, 2026: Billing and clinical staff must access the full policy text at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=12&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-01-33l to review updated medical necessity criteria for Leuprolide products. Providers must document medical necessity according to new guidelines for all Leuprolide claims submitted after 12/29/2025. Update prior authorization templates and clinical documentation requirements in the EMR to reflect new criteria. Train billing staff on any new approval workflows. Claims submitted without updated medical necessity documentation may be denied.